UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 94-3078125 (State or Other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of ...

Financial Performance - The net loss for the three months ended March 31, 2020, was $2,205,000, compared to a net loss of $1,961,000 for the same period in 2019, indicating an increase in loss of about 12.4%[11] - The company reported a basic and diluted net loss per share of $0.31 for the three months ended March 31, 2020, compared to $0.48 for the same period in 2019, showing an improvement of about 35.4%[11] - The company experienced net cash flows from operating activities of $(5,921,000) for the three months ended March 31, 2020, compared to $(2,723,000) for the same period in 2019, indicating a worsening cash flow situation[21] - The net loss for the three months ended March 31, 2020, was $2,205,000, compared to a net loss of $1,961,000 for the same period in 2019, reflecting an increase in losses[11] - The company reported net cash flows from operating activities of $(5,921,000) for the three months ended March 31, 2020, compared to $(2,723,000) for the same period in 2019, indicating a significant increase in cash outflows[21] Assets and Liabilities - As of March 31, 2020, total assets decreased to $31,298,000 from $37,126,000 as of December 31, 2019, representing a decline of approximately 15.7%[9] - Total current liabilities decreased significantly to $927,000 as of March 31, 2020, from $4,826,000 as of December 31, 2019, a reduction of approximately 80.8%[9] - The total stockholders' equity decreased to $29,678,000 as of March 31, 2020, down from $31,540,000 as of December 31, 2019, a decline of approximately 5.9%[9] - The company's total liabilities decreased to $1,620,000 as of March 31, 2020, from $5,586,000 as of December 31, 2019[9] - Total current assets decreased to $30,103,000 as of March 31, 2020, from $35,936,000 as of December 31, 2019[9] Cash and Cash Equivalents - Cash and cash equivalents at the end of the period were $29,585,000, an increase from $28,771,000 at the end of 2019, representing a growth of about 2.8%[9] - As of March 31, 2020, the company had unrestricted cash and cash equivalents of approximately $29,661,000, which is expected to fund operations for more than 12 months[29] - The company reported cash, cash equivalents, and restricted cash at the beginning of the period as $33,129,000, down to $29,661,000 at the end of the period, indicating a decrease of approximately 11.8%[21] Research and Development - Research and development expenses increased to $691,000 for the three months ended March 31, 2020, up from $587,000 in the same period of 2019, reflecting a growth of approximately 17.7%[11] - The company expects to continue incurring additional losses due to ongoing research and development activities, indicating a need for potential future capital raises through debt or equity securities[30] - The company has received grants from the Israeli Innovation Authority totaling approximately $1,500, with a royalty obligation of 3%-3.5% of future sales[54] - The Company is collaborating with Washington University on a research agreement with total expected costs of approximately $248, ongoing until March 15, 2021[58] - The Company has a research agreement with Wayne State University with total expected costs of approximately $343 for ongoing phases of research[60] Compensation and Salaries - The CEO's annual base salary was increased from $360,000 to $450,000, retroactive to January 1, 2020[78] - The company recognized compensation expenses of $144 related to stock options granted to the CEO as of March 31, 2020[93] - The company recorded a compensation expense of $343,000 for stock-based employee compensation awards for the three months ended March 31, 2020, compared to $315,000 for the same period in 2019[101] - The company incurred share-based compensation expenses of $343,000 for the three months ended March 31, 2020, compared to $315,000 for the same period in 2019, reflecting a 8.9% increase[21] - The Company had approximately $2,267,000 of total unrecognized compensation costs related to unvested share-based compensation awards, expected to be recognized over a weighted average period of 1.11 years[98] Stock Options and Shares - As of March 31, 2020, the total outstanding stock options increased to 537,061 from 371,360 at the beginning of the period, with a weighted average exercise price of $9.35[100] - The aggregate intrinsic value of outstanding options as of March 31, 2020, was $456,000, down from $761,000 in 2019, while the intrinsic value of exercisable options was $446,000 compared to $761,000 in 2019[97] - The weighted average remaining contractual life of outstanding stock options was 7.3 years as of March 31, 2020[100] - The Company granted stock options to purchase 166,666 shares at an exercise price of $9.64 on February 25, 2020[93] - The Company had outstanding warrants totaling 183 as of March 31, 2020, with an exercise price of $2,754.00[103] Legal and Financial Obligations - The company paid approximately $3,700 to Sabby Healthcare Master Fund Ltd. for 83,333 shares of common stock following a lawsuit judgment[65] - The company is seeking to divest approximately $468 in short swing profits from Alliance Investment Management, Ltd.[66] - The Company has no obligation to repay government grants if the research and development projects fail or do not generate sales[55] - The Company is involved in litigation related to a rescinded Securities Purchase Agreement, with a payment of approximately $3,700 made to Sabby Healthcare Master Fund Ltd.[65] - The Company is seeking to recover approximately $468,000 in profits from Alliance Investment Management, Ltd. related to short swing trading violations[66] Business Operations and Market Conditions - The company has not generated any revenues from its operations to date, highlighting its pre-clinical stage in the medical device market[29] - The ongoing COVID-19 pandemic may cause significant delays and disruptions to clinical trials, impacting the company's ability to conduct business effectively[31] - The company may face challenges in raising additional capital due to market demand and business risks[30] - The Company is focused on developing next-generation micro-robotics assisted medical technologies targeting minimally invasive surgery, aiming to redefine surgical robotics and improve patient outcomes[23] - The Company is focused on developing next-generation micro-robotics assisted medical technologies targeting minimally invasive surgery, aiming to improve surgical outcomes[23]

PART I [Business](index=4&type=section&id=Item%201.%20Business) Microbot Medical Inc. develops micro-robotic endoluminal surgery devices, focusing on SCS for hydrocephalus and Liberty for endovascular procedures [Company Overview](index=4&type=section&id=The%20Company) Microbot is a pre-clinical medical device company focused on developing robotic endoluminal surgery devices, including SCS and Liberty systems - Microbot is a pre-clinical medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices[18](index=18&type=chunk) - The company's main product development efforts are focused on the Self Cleaning Shunt (SCS) for hydrocephalus and the Liberty™ system, a fully disposable robot for endovascular procedures[19](index=19&type=chunk) - The company's intellectual property portfolio consists of **37 issued/allowed patents** and **15 pending patent applications** worldwide[20](index=20&type=chunk) [Technological Platforms](index=4&type=section&id=Technological%20Platforms) The company's technology is built on four main platforms: ViRob, TipCAT, CardioSert, and Liberty, integrating acquired and developed systems for endoluminal procedures - ViRob is an autonomous crawling micro-robot designed to navigate within human body spaces like blood vessels and is the basis for the SCS product[23](index=23&type=chunk) - TipCAT is a self-propelled locomotive device using interconnected balloons for forward motion in tubular anatomies, designed to reduce lumen damage[25](index=25&type=chunk) - CardioSert technology, acquired in May 2018, features a guidewire delivery system with controllable tip curvature and stiffness, initially for cardiology but with potential in neurosurgery[26](index=26&type=chunk) - Liberty, unveiled in January 2020, is a compact, fully disposable robotic system for endovascular procedures, designed to be operated remotely and reduce radiation exposure for physicians[28](index=28&type=chunk) [Product Pipeline](index=8&type=section&id=Our%20Product%20Pipeline) The company's pipeline is led by the Self-Cleaning Shunt (SCS) for hydrocephalus and the Liberty robotic system for endovascular interventions - The Self-Cleaning Shunt (SCS) is designed to be a universal ventricular catheter component that uses an internal robotic mechanism to prevent blockages in CSF shunts[47](index=47&type=chunk)[48](index=48&type=chunk) - Pre-clinical in-vitro studies for the SCS have shown its potential to prevent shunt occlusion, and follow-up studies are underway to validate safety and efficacy for regulatory submissions[50](index=50&type=chunk)[51](index=51&type=chunk)[52](index=52&type=chunk) - The Liberty robotic system is a fully disposable, compact system for endovascular procedures, designed to reduce capital equipment needs and improve operator safety, featuring a 'One & Done' tool combining a guidewire and microcatheter[58](index=58&type=chunk) - The company plans to commence animal trials for the Liberty device as early as Q1 2021, with a potential FDA submission in Q4 2021[59](index=59&type=chunk) [Competition](index=13&type=section&id=Competition) Microbot faces competition for its SCS device from Anuncia Inc. and Aqueduct Neurosciences, and for its Liberty system from Corindus Vascular Robotics and others - The SCS device faces potential direct competition from Anuncia Inc.'s Alivio ReFlow™ Ventricular System and non-direct competition from Aqueduct Neurosciences' non-shunt technology[67](index=67&type=chunk) - The primary competitor for the Liberty robotic system is the CorPath GRX system from Corindus Vascular Robotics (Siemens); other competitors include Robocath and Hansen Medical (J&J)[71](index=71&type=chunk) - The company believes existing robotic systems have drawbacks such as being cumbersome, requiring significant capital expenditure, and having limited maneuverability, which Liberty aims to address[71](index=71&type=chunk) [Intellectual Property](index=14&type=section&id=Intellectual%20Property) The company's intellectual property strategy relies on licensed technology, internal development, patents, and trade secrets, with 37 issued/allowed patents and 15 pending applications - The company holds an IP portfolio of **37 issued/allowed patents** and **15 pending applications** worldwide[74](index=74&type=chunk) - The SCS and TipCAT technologies are exclusively licensed from TRDF, requiring meeting development milestones, including commencing first-in-human clinical trials by December 2021, to avoid termination[81](index=81&type=chunk) - Under the TRDF agreement, Microbot is obligated to pay royalties of **1.5% to 3.0%** on net sales of licensed products[82](index=82&type=chunk) - The company's issued U.S. patents covering its product candidates will expire between **2026 and 2033**[80](index=80&type=chunk) [Research and Development](index=15&type=section&id=Research%20and%20Development) Research and development is a primary focus, with expenses increasing to **$3.0 million** in 2019 from **$2.5 million** in 2018, supported by Israeli Innovation Authority grants Research and Development Expenses | Expense Category | 2019 | 2018 | | :--- | :--- | :--- | | Research and Development | $3,048,000 | $2,515,000 | - The company has received approximately **$1.5 million** in grants from the Israeli Innovation Authority (IIA) through December 31, 2019. These grants are repayable via royalties of **3%-3.5%** on future sales[86](index=86&type=chunk) - The company has submitted existing SCS animal trial data to the FDA in a pre-submission meeting to seek an Early Feasibility Study (EFS), with a goal to commence controlled human trials under an EFS as early as Q3 2022[94](index=94&type=chunk) [Government Regulation](index=18&type=section&id=Government%20Regulation) Microbot's products are subject to extensive regulation by the FDA in the U.S. and similar authorities abroad, with expected classification as Class II medical devices - Products are subject to extensive regulation by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FDCA)[103](index=103&type=chunk) - The company expects its products to be classified as Class II devices, requiring either a 510(k) premarket notification or a de novo clearance from the FDA before commercial distribution[109](index=109&type=chunk) - For commercialization in Europe, a CE Mark certificate is required, which verifies compliance with the Medical Device Regulation (MDR 2017/745)[130](index=130&type=chunk) - In Israel, medical devices must be registered with the Ministry of Health (MOH) through its AMAR department, a process that is expedited if the device has approval from a 'recognized' country like the U.S. or E.U[131](index=131&type=chunk)[132](index=132&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks, including operating losses, need for additional capital, COVID-19 disruptions, development and regulatory hurdles, and intellectual property challenges [Risks Relating to Financial Position and Need for Additional Capital](index=25&type=section&id=Risks%20Relating%20to%20Microbot's%20Financial%20Position%20and%20Need%20for%20Additional%20Capital) Microbot is a development-stage company with no revenue and a history of significant operating losses, requiring additional funding to support its development programs - The company has incurred significant operating losses since inception, generates no revenue, and may never achieve or sustain profitability[140](index=140&type=chunk)[141](index=141&type=chunk) - Additional funding will be needed to continue operations, and an inability to raise capital on attractive terms could force the company to delay, reduce, or eliminate product development or commercialization[145](index=145&type=chunk)[146](index=146&type=chunk) - The COVID-19 pandemic may cause significant disruptions to clinical trials, patient enrollment, and supply chains, which could materially adversely affect the business[151](index=151&type=chunk)[152](index=152&type=chunk)[153](index=153&type=chunk) [Risks Relating to the Development and Commercialization of Product Candidates](index=28&type=section&id=Risks%20Relating%20to%20the%20Development%20and%20Commercialization%20of%20Microbot's%20Product%20Candidates) The company's success is heavily dependent on its lead candidates, SCS and Liberty, facing risks from inconclusive trials, regulatory hurdles, competition, and reliance on third-party manufacturers - Interim data from the SCS animal trial was inconclusive for assessing safety, leading the company to seek an Early Feasibility Study (EFS) from the FDA, which may not be granted[154](index=154&type=chunk)[156](index=156&type=chunk) - The FDA may not agree with the company's classification of the SCS as a Class II device, potentially requiring a more burdensome De Novo or PMA submission process, which would increase costs and delay commercialization[166](index=166&type=chunk)[167](index=167&type=chunk) - The acquired CardioSert technology is subject to a buy-back clause if commercialization deadlines (starting January 2021) are not met, which could jeopardize the Liberty device development[171](index=171&type=chunk)[172](index=172&type=chunk) - The company relies on third-party manufacturers, which entails risks related to supply availability, quality control, and potential termination of agreements[181](index=181&type=chunk) [Risks Relating to Intellectual Property](index=40&type=section&id=Risks%20Relating%20to%20Microbot's%20Intellectual%20Property) The company's rights to develop SCS and TipCAT depend on a TRDF license, which can be terminated if development milestones are not met, alongside risks of litigation and patent protection challenges - The license for SCS and TipCAT technologies from TRDF requires meeting development milestones, including commencing first-in-human clinical trials by December 2021, to avoid termination of the license[213](index=213&type=chunk) - The medical device industry is characterized by extensive intellectual property litigation, which could lead to significant expenses and prevent the sale of products[219](index=219&type=chunk) - The company's success depends on its ability to obtain and maintain patent protection and trade secrets for its technologies, which is a lengthy and costly process with no guarantee of success[220](index=220&type=chunk)[221](index=221&type=chunk) [Risks Relating to Operations in Israel](index=42&type=section&id=Risks%20Relating%20to%20Operations%20in%20Israel) Microbot's operations in Israel expose it to regional instability, foreign currency exchange risk, restrictions from government grants, and employee military reserve duty obligations - Political, economic, and military conditions in Israel, where the company has facilities and key personnel, could directly and adversely affect operations[227](index=227&type=chunk) - A significant portion of expenses are in New Israeli Shekels (NIS), exposing the company to foreign currency exchange rate fluctuations against the U.S. dollar[230](index=230&type=chunk) - Funding from the Israeli Innovation Authority (approx. **$1.5 million** through 2019) comes with restrictions on transferring technology or manufacturing outside Israel and requires royalty payments on future sales[234](index=234&type=chunk)[235](index=235&type=chunk) [Properties](index=46&type=section&id=Item%202.%20Properties) Microbot does not own real property, with its principal executive office in Hingham, Massachusetts, and leased facility space in Yokneam, Israel - The company's principal executive office is at 25 Recreation Drive, Unit 108, Hingham, MA 02043[246](index=246&type=chunk) - The company leases approximately **6,975 square feet** of facility space in Yokneam, Israel[246](index=246&type=chunk) [Legal Proceedings](index=46&type=section&id=Item%203.%20Legal%20Proceedings) The company is involved in significant litigation, including a **$3.7 million** payment for a rescinded 2017 financing, a new **$6.75 million** lawsuit from other investors, and a short-swing profit lawsuit with a counterclaim - Following a lost appeal, the company paid approx. **$3.7 million** to Sabby entities to rescind their participation in a June 2017 financing[248](index=248&type=chunk) - The company is now being sued by other investors from the same 2017 financing (Empery and Hudson Bay) who are seeking the return of their **$6.75 million** purchase price[248](index=248&type=chunk) - The company has sued Alliance Investment Management to disgorge approx. **$480,000** in alleged short-swing profits, which has led to a counterclaim against Microbot by Joseph Mona[249](index=249&type=chunk)[253](index=253&type=chunk) PART II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=47&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on NASDAQ under 'MBOT' with approximately **150** record holders, no history of cash dividends, and details on equity compensation plans - The company's common stock trades on the NASDAQ Capital Market under the symbol 'MBOT'[259](index=259&type=chunk) - As of April 9, 2020, there were approximately **150** holders of record of the common stock[260](index=260&type=chunk) - The company has never paid cash dividends and does not plan to in the foreseeable future[261](index=261&type=chunk) Securities Available for Issuance Under Equity Compensation Plans | Plan Category | Securities to be issued upon exercise | Weighted-average exercise price | Securities remaining available for future issuance | | :--- | :--- | :--- | :--- | | Equity compensation plans approved by security holders | 230,972 | $13.4 | 252,357 | | Equity compensation plans not approved by security holders | 140,388 | $2.3 (calculated) | - | | **Total** | **371,360** | | **252,357** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=49&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Microbot, a pre-clinical medical device company, reported a net loss of **$7.2 million** in 2019, with increased R&D expenses and decreased G&A expenses, and a working capital of **$31.1 million** [Results of Operations](index=52&type=section&id=Results%20of%20Operations) For the year ended December 31, 2019, research and development expenses increased by **$533,000** to **$3.05 million**, while general and administrative expenses decreased by **$537,000** to **$4.19 million** Operating Expenses Summary | (in thousands) | 2019 | 2018 | Increase/(Decrease) | | :--- | :--- | :--- | :--- | | Research and development expenses | $3,048 | $2,515 | $533 | | General and administrative expenses | $4,192 | $4,729 | $(537) | | Financing (income) expenses, net | $103 | $16 | $87 | | Capital (Gain) Loss | $(96) | $- | $(96) | - The increase in R&D expenses in 2019 was primarily due to an increase in materials and professional services[288](index=288&type=chunk) - The decrease in G&A expenses in 2019 was primarily due to lower share-based compensation and public relations costs[289](index=289&type=chunk) [Liquidity and Capital Resources](index=52&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2019, Microbot had working capital of approximately **$31.1 million**, believing it sufficient for at least **24 months**, though pending litigation could impact this - As of December 31, 2019, the company had net working capital of approximately **$31,110,000**[292](index=292&type=chunk) - The company believes its cash will be sufficient to fund operations for at least **24 months**, but notes that losing the pending litigation for **$6.75 million** could reduce this period[295](index=295&type=chunk) Cash Flow Summary | (in thousands) | 2019 | 2018 | | :--- | :--- | :--- | | Net cash used in operating activities | $(6,451) | $(5,310) | | Net cash used in investing activities | $(2,453) | $(223) | | Net cash from financing activities | $36,770 | $(18) | | **Net increase (decrease) in cash** | **$27,866** | **$(5,551)** | [Quantitative and Qualitative Disclosures About Market Risk](index=54&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's primary market risks are interest rate sensitivity on cash and foreign exchange rate fluctuations due to expenses in non-U.S. dollar currencies - The company's primary market risk is interest income sensitivity on its cash and cash equivalents, but due to their short-term nature, the impact of rate changes is expected to be minimal[301](index=301&type=chunk) - The company is exposed to foreign exchange risk as a significant portion of its operating expenses are payable in currencies other than the U.S. dollar[302](index=302&type=chunk) [Controls and Procedures](index=55&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and internal control over financial reporting were effective as of December 31, 2019, with no material changes in the last fiscal quarter - Management concluded that as of December 31, 2019, the company's disclosure controls and procedures were effective[307](index=307&type=chunk) - Management concluded that as of December 31, 2019, the company's internal control over financial reporting was effective[308](index=308&type=chunk) - There were no changes in internal control over financial reporting during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, internal controls[310](index=310&type=chunk) PART III [Directors, Executive Officers, and Corporate Governance](index=55&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%2C%20and%20Corporate%20Governance) Information regarding directors, executive officers, and corporate governance is incorporated by reference from the company's 2020 Proxy Statement - The information required by this item is incorporated by reference from the company's 2020 Proxy Statement[313](index=313&type=chunk) [Executive Compensation](index=55&type=section&id=Item%2011.%20Executive%20Compensation) Information regarding director and executive compensation is incorporated by reference from the company's 2020 Proxy Statement - The information required by this item is incorporated by reference from the company's 2020 Proxy Statement[315](index=315&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=56&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information regarding security ownership of certain beneficial owners and management is incorporated by reference from the company's 2020 Proxy Statement - The information required by this item is incorporated by reference from the company's 2020 Proxy Statement[316](index=316&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=56&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information regarding certain relationships, related transactions, and director independence is incorporated by reference from the company's 2020 Proxy Statement, listing independent board members - The information required by this item is incorporated by reference from the company's 2020 Proxy Statement[317](index=317&type=chunk) - The independent directors are listed as Messrs. Waizer, Bornstein, Burell, Madden and Laxminarain, and Ms. Aileen Stockburger[319](index=319&type=chunk) [Principal Accountant Fees and Services](index=56&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information regarding principal accountant fees and services is incorporated by reference from the company's 2020 Proxy Statement - The information required by this item is incorporated by reference from the company's 2020 Proxy Statement[320](index=320&type=chunk) PART IV [Exhibits and Financial Statement Schedules](index=56&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists the financial statements and exhibits filed as part of the Annual Report on Form 10-K, including corporate governance documents and material contracts - This item lists the financial statements and exhibits filed as part of the Form 10-K[322](index=322&type=chunk) Financial Statements [Consolidated Balance Sheets](index=62&type=section&id=Consolidated%20Balance%20Sheets) As of December 31, 2019, total assets increased to **$37.1 million** from **$6.1 million** in 2018, driven by a rise in cash and cash equivalents, with stockholders' equity increasing to **$31.5 million** Balance Sheet Highlights | (U.S. dollars in thousands) | Dec 31, 2019 | Dec 31, 2018 | | :--- | :--- | :--- | | **Total current assets** | **$35,936** | **$5,831** | | Total assets | $37,126 | $6,090 | | **Total current liabilities** | **$4,826** | **$4,760** | | Total liabilities | $5,586 | $4,760 | | **Total stockholders' equity** | **$31,540** | **$1,330** | | Total liabilities and stockholders' equity | $37,126 | $6,090 | [Consolidated Statements of Operations](index=63&type=section&id=Consolidated%20Statements%20of%20Operations) For the year ended December 31, 2019, the company reported a net loss of **$7.247 million**, nearly identical to 2018, with a basic and diluted net loss per share of **$1.70** Statements of Operations Summary | (U.S. dollars in thousands) | 2019 | 2018 | | :--- | :--- | :--- | | Research and development | $3,048 | $2,515 | | General and administrative | $4,192 | $4,729 | | **Operating loss** | **$(7,240)** | **$(7,244)** | | **Net loss** | **$(7,247)** | **$(7,260)** | | Basic and diluted net loss per share | $(1.70) | $(2.41) | [Consolidated Statements of Cash Flows](index=66&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the year ended December 31, 2019, net cash used in operating activities was **$6.5 million**, while net cash provided by financing activities was **$36.8 million**, resulting in a **$27.9 million** increase in cash Cash Flow Activities | (U.S. dollars in thousands) | 2019 | 2018 | | :--- | :--- | :--- | | Net cash used in operating activities | $(6,451) | $(5,310) | | Net cash used in investing activities | $(2,453) | $(223) | | Net cash from financing activities | $36,770 | $(18) | | **Increase (decrease) in cash, cash equivalents and restricted cash** | **$27,866** | **$(5,551)** | | Cash, cash equivalents and restricted cash at end of period | $33,129 | $5,263 | [Notes to Consolidated Financial Statements](index=67&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail accounting policies, business risks, and financial line items, including the company's pre-revenue status, government grant obligations, significant litigation, and 2019 equity offerings - The company has not generated revenues and management believes its cash balance of **$28.7 million** as of Dec 31, 2019 is sufficient to fund operations for more than 12 months (Note 1)[361](index=361&type=chunk) - The company is obligated to pay royalties of **3%-3.5%** on future sales up to the grant amount of approx. **$1.5 million** received from the Israeli Innovation Authority (IIA) (Note 8)[418](index=418&type=chunk) - The company is a defendant in a lawsuit seeking the return of a **$6.75 million** investment from a 2017 financing, following a prior adverse judgment that resulted in a payment of approx. **$3.7 million** to another investor from the same financing (Note 8)[428](index=428&type=chunk) - In 2019, the company raised gross proceeds of approximately **$28 million** through multiple registered direct offerings of common stock and warrants (Note 9)[445](index=445&type=chunk)[446](index=446&type=chunk)[447](index=447&type=chunk)[448](index=448&type=chunk)[449](index=449&type=chunk)[450](index=450&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 25 Recreat ...

Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 94-3078125 (State or Other ...